• Autism is increasingly recognised as an immune-related disorder rather than solely a neurological one.
• Many children with autism show chronic inflammation, gut dysbiosis, and immune deficiencies—all of which VDTP/GcMAF helps to modulate.
• Conventional treatments (ABA therapy, behavioural interventions) do not address underlying immune dysfunction—while immune-modulating approaches have demonstrated potential in both research and real-world settings.

Why This Matters:

• If immune dysfunction contributes to autism, restoring immune balance could be a major breakthrough.
• Instead of investigating VDTP/GcMAF as a safe intervention, regulators shut it down—despite its natural role in human biology.

3. Suppression & The Hypocrisy of Regulation

• If VDTP/GcMAF was a synthetic drug patented by a pharmaceutical company, it would likely be available as an FDA-approved autism treatment.
• Because it is natural and cannot be patented, it has been regulated out of existence—even as countless parents seek real solutions for their children.
• The crackdown on GcMAF research has prevented families from accessing a potentially life-changing intervention.

Regulatory Double Standard:

• Other immune-based interventions (like IVIG or anti-inflammatory drugs) are used in autism treatment despite significant side effects.
• VDTP/GcMAF, with a strong safety profile, was not given the same consideration—instead, it was labelled “dangerous” despite being naturally present in the body.
• This suggests regulation was not about safety but maintaining control over medical treatments.

---

Closing Argument: A Denial of Hope & Progress

If immune dysfunction is a key factor in autism, and VDTP/GcMAF has demonstrated real potential in addressing it, then suppressing it is not just scientific negligence—it is a denial of hope for thousands of families.This is not just a regulatory debate.
It is a question of ethics, human rights, and the right of every family to seek the best care for their children.